|
|
|
|
|
|
Product Valuation: Health Advances was asked to provide a detailed market analysis and product concept refinement for two early-stage, next-generation,
and supportive-care oncology products. The Health Advances team spoke with hematologists and medical oncologists in the US, Europe, and Japan to map current treatment
pathways for chemotherapy and bone marrow/stem cell transplant patients, estimated potential patient populations, determined dosing and pricing estimates, and identified
red flags in the product concepts for each of the different geographies. Once the market was sufficiently characterized, Health Advances used this knowledge to forecast
the products' potential costs and revenues. Health Advances used this information to drive a Monte Carlo analysis and generate a risk-adjusted NPV model.
Deal Negotiations: A small biotech company was in the process of licensing a hand-held device to count white blood cells. Health Advances was hired to help
the client quantify the device's market potential for the purpose of negotiating the most favorable deal terms. Health Advances interviewed oncologists and infectious disease
specialists to map out the current treatment pathway and identified the patient population in which this cell-monitoring device would create a clinical benefit, as well as cost
benefit. Health Advances projected pricing by evaluating system economic factors, as well as analog products and current therapies. The client used Health Advances's market sizing
estimates to assist in their negotiations with the licensor.
Financial Modeling of Synergy Potential for an Acquisition Target: A private equity firm engaged Health Advances to evaluate a potential investment in a specialty
generics company, focused on the treatment of hepatitis C that used the specialty pharmacy channel as the main outlet for its products. As part of the analysis, Health Advances
examined the potential synergy of combining the company's existing business with an in-process acquisition. Using a series of physician and industry interviews, combined with
extensive secondary research, Health Advances identified several key areas of instability within the target company's base business, and quantified the upside and downside
scenarios for this business in it current state. These insights, supported by a strong fact basis, tempered the client's enthusiasm for the target's current value but Health
Advances developed a strategically focused opportunity screen to identify potential candidates to add scale to the base business sufficient to leverage the proposed salesforce
and create more value.
Outsourced Business Development Support: Health Advances directed the business development effort leading to the sale of a medical device company. Involved from
the earliest stages of the decision to seek a partner or exit strategy, Health Advances valued the company portfolio, prepared the road show presentation, identified target
companies, approached the companies to investigate their interest, conducted due diligence on several companies, and supported the final negotiations.
Valuation of a Novel Cardiopulmonary Bypass Oxygenator: For a strategic buyer, Health Advances forecasted the revenues of an improved oxygenator that appeared
to reduce the peripheral damage caused by traditional cardiopulmonary bypass circuits during major cardiothoracic procedures. In addition to estimating future penetration of
the market, the study also sought to forecast the future volumes of these procedures in light of changing demographics and inroads of interventional procedures.
|
|
 |
|
|
|
|
